Capital World Investors
EIKN

Capital World Investors’s Eikon Therapeutics EIKN Stock Holding History

Capital World Investors’s Portfolio EIKN Stock Details EIKN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.3M Buy
1,175,944
+32,307
+3% +$330K ﹤0.01% 565
2026
Q1 		$12.1M Buy
+1,143,637
New +$15.3M ﹤0.01% 555

Other funds holding EIKN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Capital World Investors's EIKN Position: Q2 2026 in Review

Capital World Investors increased its Eikon Therapeutics (EIKN) stake by 2.8% in Q2 2026, buying an estimated $330K and bringing the position to 1,175,944 shares worth $15.3M. The position accounts for ﹤0.01% of the portfolio, ranked #565.

Capital World Investors first reported a position in EIKN in Q1 2026 and has held it in 2 quarters since. 70 funds tracked by Wall St. Rank hold EIKN as of Q2 2026.

  • Capital World Investors held 1,175,944 shares of Eikon Therapeutics worth $15.3M as of Q2 2026.
  • Capital World Investors bought 32,307 Eikon Therapeutics shares in Q2 2026, an estimated $330K.
  • Eikon Therapeutics made up ﹤0.01% of Capital World Investors's portfolio in Q2 2026, its #565 holding.
  • Capital World Investors first reported a position in Eikon Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 70 funds tracked by Wall St. Rank held Eikon Therapeutics as of Q2 2026.

Based on Capital World Investors's 13F filing for Q2 2026, filed 12 Aug 2026.